Kineta Reports Initial Clinical Response Data at AACR 2024 :

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety...

Related Keywords

United States , San Diego , California , American , Thierry Guillaudeux , Kineta Inc , American Association For Cancer Research , Merck Sharp Dohme , Merck Co Inc , Nasdaq , American Association , Cancer Research , Dose Escalation , Therapy Dose Escalation , Chief Scientific Officer , Merck Sharp , Statements Regarding Forward Looking , Private Securities Litigation Reform Act , Annual Report , Nasdaq Ka , Vineta , Nc ,